AUA 2011 - Insight into percutaneous tibial nerve stimulation: Critical evaluation of the SUmiT Trial - Session Highlights

WASHINGTON, DC USA (UroToday.com) - This was an interesting review by Dr. Kenneth Peters, who also presented this treatment in his State-of-the Art lecture: New & Emerging Concepts in Neuromodulation on Monday’s plenary session.

The treatment discussed is the Urgent® PC percutaneous tibial nerve stimulation (PTNS) that delivers minimally invasive stimulation of the posterior tibial nerve. This is a review of the SUmiT Trial previously reported and published. Dr Peters looked at Global Response Assessment (GRA) and OAB-q quality of life responses at the 7 and 13 weeks. It was noted that 12 weekly treatment sessions are needed to effectively treat OAB. All GRA outcomes were statistically significant at 13 weeks compared to baseline, but outcomes were not significant at 7 weeks. Similarly, OAB-q quality of life questionnaires were statistically significant for improvement at 13 weeks, but not significant at 7 weeks between treatment groups.

 

Reference:
Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, Macdiarmid SA. (2010) Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 183(4):1438-43.

 

Presented by Kenneth Peters, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA

Reported for UroToday by Diane K. Newman, RNC, MSN, CRNP, FAAN and Continence Nurse Practitioner Specialist - University of Pennsylvania Medical Center.

 

The opinions expressed in this article are those of the UroToday.com Contributing Medical Editor and do not necessarily reflect the viewpoints of the American Urological Association.




View Full AUA 2011 Meeting Coverage



Supported by:  




email news signup